Menu
Oslo, Norway, 11 December 2024: Reference is made to the stock exchange announcements by Thor Medical ASA (the "Company") on 11 December 2024 regarding a private placement of new shares to be issued by the Company (the "Private Placement").
Scatec Innovation AS has agreed to lend existing and unencumbered shares in the Company, already being traded on Euronext Oslo Børs, to the manager for the Private Placement. Borrowed shares will be used for settlement towards investors having been allocated shares in the Private Placement and redelivered to Scatec Innovation AS upon registration of the share capital increase pertaining to the Private Placement.
Prior to the completion of the Private Placement, Scatec Innovation AS held 64,417,932 shares in the Company, representing approx. 27.43% of the issued share capital and votes. Scatec Innovation AS has lent a total of 45,632,920 existing shares which will be delivered to the investors in the Private Placement other than Scatec Innovation AS. During the term of the loan, and prior to the redelivery, Scatec Innovation AS' shareholding in the Company will be reduced to 18,785,012, equivalent to approx. 6.70% of the issued share capital and votes. Consequently, Scatec Innovation AS has fallen below the 25, 20, 15 and 10% threshold pursuant to section 4-2 (1) and (3) of the Norwegian Securities Trading Act.
The board of directors of the Company has resolved to issue 45,632,920 offer shares in the Private Placement pursuant to the authorisation granted by the Company's annual general meeting held on 11 April 2024, that will be subscribed by the manager and, once issued, delivered to Scatec Innovation AS as for redelivery of shares borrowed in relation to settlement of tranche 1 of the Private Placement.
This information is subject to disclosure requirements pursuant to the EU Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading Act section and 5-12.
Contacts
Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visit www.thormedical.no - https://www.thormedical.no.
